The global interventional radiology market was valued at USD 28.10 Billion in 2024 and is projected to reach USD 47.28 Billion by 2033, growing at a CAGR of 5.95% during the forecast period from 2025 to 2033. The market growth is driven by increasing preferences for minimally invasive procedures, technological advancements including AI-driven imaging, expanding telemedicine, and favorable reimbursement policies. North America leads the market with a 38.5% share in 2024.
Study Assumption Years
- Base Year: 2024
- Historical Years: 2019-2024
- Forecast Period: 2025-2033
Interventional Radiology Market Key Takeaways
- The global interventional radiology market size was USD 28.10 Billion in 2024.
- The market is expected to grow at a CAGR of 5.95% during 2025-2033.
- North America dominated with a 38.5% market share in 2024.
- Increasing incidence of chronic diseases like cardiovascular disorders and cancer drives demand for minimally invasive treatments.
- Technological innovations such as AI integration and augmented reality enhance procedural precision and workflow efficiency.
- Expanding telemedicine and favorable reimbursement policies improve patient access and adoption.
- Hybrid imaging technologies and medical training programs support market expansion in precision and minimally invasive procedures.
Sample Request Link:
https://www.imarcgroup.com/interventional-radiology-market/requestsample
Market Growth Factors
The interventional radiology market is propelled by rising prevalence of chronic illnesses such as cardiovascular diseases and cancer, which escalate the need for minimally invasive (MI) treatments. For example, the growing occurrence of coronary artery disease and stroke increases demand for angioplasty and catheter-based interventions. Rising cancer prevalence fosters adoption of tumor ablation, chemoembolization, and radioembolization techniques. Additionally, the aging population vulnerable to these diseases further intensifies demand for MI procedures, which reduce complications and speed recovery compared to traditional open surgeries.
Technological advancements play a pivotal role in market growth. Innovations in artificial intelligence (AI) are improving imaging accuracy and procedural efficiency through real-time analysis and workflow automation. Augmented reality (AR) assists with spatial awareness and precision during interventions, reducing radiation exposure. Hybrid imaging, including PET-CT and MRI-guided interventions, enhances localization and targeting in oncology. Robotics-assisted systems and cloud-based PACS solutions contribute to improved procedural outcomes and remote diagnostics. These developments are transforming interventional radiology practices and expanding treatment options.
Favorable reimbursement policies, growing telemedicine capabilities, and increasing healthcare infrastructure investments facilitate market expansion. Telemedicine improves access to image-guided treatments in underserved regions. Regulatory approvals for innovative devices and AI-driven imaging solutions encourage patient adoption. Medical training programs enhance the expertise of radiologists in MI techniques. Governments and healthcare providers are supporting early disease detection initiatives and insurance coverage for such procedures, making advanced interventional radiology more accessible and affordable worldwide.
Market Segmentation
By Product:
- Magnetic Resonance Imaging (MRI): Dominates due to superior, non-invasive imaging with high-resolution and no radiation, widely used for neurological, cardiovascular, musculoskeletal, and oncology applications with ongoing technological advancements.
- Ultrasound Imaging Systems
- Computed Tomography (CT) Scanners
- Angiography Systems
- Fluoroscopy Systems
- Biopsy Devices
- Others
By Procedures:
- Angiography: Holds 31.2% market share in 2024, enables precise visualization of blood vessels for cardiovascular disease detection, supported by digital subtraction angiography advancements and minimally invasive catheter techniques.
- Angioplasty
- Embolization
- Vertebroplasty
- Thrombolysis
- Nephrostomy Placement
- Others
By Application:
- Cardiology: Central in diagnosing and treating cardiovascular diseases using angiography, stenting, and embolization with AI-assisted imaging.
- Urology and Nephrology: Procedures like renal angioplasty and embolization address kidney stones, stenosis, and obstructions, improving recovery.
- Oncology: Used for tumor detection, biopsy guidance, and MI cancer treatments, including radiofrequency ablation and chemoembolization, boosted by AI and hybrid imaging.
- Gastroenterology: Enables bile duct stenting, gastrointestinal bleeding embolization, and liver biopsies with enhanced imaging accuracy and minimally invasive options.
- Others
By End Use:
- Hospitals: Lead with 53.2% market share in 2024, equipped with advanced radiology departments, supporting complex diagnostic and therapeutic interventions.
- Clinics
- Ambulatory Surgical Centers
Regional Insights
North America is the dominant region with a 38.5% market share in 2024. The region benefits from the presence of leading medical device companies, rising incidence of cardiovascular diseases and cancer, favorable reimbursement policies, strong healthcare investments, and advanced R&D initiatives. Technological innovations like AI and hybrid imaging improve procedural precision. The aging population and expanding telemedicine services further reinforce North America’s market leadership.
Recent Developments & News
- November 2024: Philips India launched the Azurion interventional radiology system to enhance neurovascular procedures with advanced C-arm rotation and AI-powered remote monitoring.
- October 2024: VA Boston Healthcare System opened a new interventional radiology suite to improve Veteran care with minimally invasive treatments.
- June 2024: GE HealthCare and MediView XR Inc. installed the first OmnifyXR interventional suite at North Star Vascular and Interventional, expanding precision imaging capabilities.
- June 2024: Royal Philips performed the first implantation of the Duo Venous Stent System for chronic venous insufficiency after FDA premarket approval, boosting its vascular treatment portfolio.
Key Players
- Boston Scientific Corporation
- Cook Group Incorporated
- Esaote SpA
- Fujifilm Holdings Corporation
- General Electric Company
- Hologic Inc
- Koninklijke Philips N.V.
- Medtronic plc
- Nipro Corporation
- Shimadzu Corporation
- Siemens Aktiengesellschaft
- Teleflex Incorporated
Ask for Report Customization:
https://www.imarcgroup.com/request?type=report&id=5636&flag=E
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302